{"id":"dexamethasone-mouthwash","safety":{"commonSideEffects":[{"rate":null,"effect":"Oral candidiasis (thrush)"},{"rate":null,"effect":"Local irritation or burning"},{"rate":null,"effect":"Taste disturbance"}]},"_chembl":{"chemblId":"CHEMBL1697787","moleculeType":"Small molecule","molecularWeight":"528.57"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Dexamethasone binds to glucocorticoid receptors in oral tissues, reducing the production of pro-inflammatory cytokines and inhibiting immune cell infiltration. This anti-inflammatory action helps reduce swelling, pain, and erythema in oral conditions. The topical formulation delivers the drug directly to affected oral tissues while minimizing systemic absorption.","oneSentence":"Dexamethasone is a corticosteroid that suppresses local inflammation and immune responses in the oral cavity when applied topically as a mouthwash.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:28:05.632Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Oral inflammation and ulceration"},{"name":"Aphthous ulcers"},{"name":"Oral lichen planus"},{"name":"Post-operative oral inflammation"}]},"trialDetails":[{"nctId":"NCT06841354","phase":"PHASE3","title":"A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-03-16","conditions":"Triple Negative Breast Neoplasms","enrollment":1000},{"nctId":"NCT06966700","phase":"PHASE3","title":"A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-06-30","conditions":"Breast Neoplasms, Triple Negative Breast Neoplasms, HR Low-Positive/HER2-Negative Breast Neoplasms","enrollment":2400},{"nctId":"NCT06305754","phase":"PHASE3","title":"Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-06-11","conditions":"Non-small Cell Lung Cancer (NSCLC)","enrollment":520},{"nctId":"NCT06824467","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-04-09","conditions":"Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer","enrollment":770},{"nctId":"NCT06312137","phase":"PHASE3","title":"A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-04-03","conditions":"Non Small Cell Lung Cancer","enrollment":780},{"nctId":"NCT07318558","phase":"PHASE3","title":"A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2026-02-16","conditions":"Ovarian Neoplasms, Ovarian Cancer","enrollment":900},{"nctId":"NCT05319730","phase":"PHASE1, PHASE2","title":"A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-05-16","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":230},{"nctId":"NCT07216703","phase":"PHASE3","title":"A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2026-01-19","conditions":"Cervical Cancer","enrollment":1023},{"nctId":"NCT06445972","phase":"PHASE1, PHASE2","title":"Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-08-07","conditions":"Gastroesophageal Junction, Gastroesophageal Adenocarcinoma, Esophageal Neoplasms","enrollment":210},{"nctId":"NCT07286149","phase":"PHASE1, PHASE2","title":"A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2026-03-23","conditions":"Lung Neoplasm Malignant","enrollment":190},{"nctId":"NCT06382948","phase":"PHASE3","title":"Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.","status":"RECRUITING","sponsor":"MedSIR","startDate":"2024-12-05","conditions":"Advanced Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer","enrollment":240},{"nctId":"NCT06788912","phase":"PHASE2","title":"Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-03-20","conditions":"Lung Neoplasm Malignant","enrollment":60},{"nctId":"NCT06356311","phase":"PHASE3","title":"A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-05-03","conditions":"Gastroesophageal Cancer","enrollment":450},{"nctId":"NCT06637423","phase":"PHASE1, PHASE2","title":"A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-12-20","conditions":"Non-Muscle Invasive Bladder Cancer","enrollment":32},{"nctId":"NCT07419295","phase":"PHASE3","title":"A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)","status":"NOT_YET_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2026-03-17","conditions":"Bladder Cancer","enrollment":590},{"nctId":"NCT07287826","phase":"PHASE4","title":"Using a Steroid Mouthwash to Prevent Mouth Sores During Chemotherapy","status":"NOT_YET_RECRUITING","sponsor":"Woman's","startDate":"2026-02","conditions":"Oral Mucositis Due to Chemotherapy","enrollment":45},{"nctId":"NCT05306340","phase":"PHASE3","title":"A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genentech, Inc.","startDate":"2022-08-03","conditions":"Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer","enrollment":373},{"nctId":"NCT07357597","phase":"PHASE4","title":"An Open-label, Single-arm Study of Prophylaxis for Datopotamab Deruxtecan (Dato-DXd) -Related Stomatitis in Eligible Patients With Metastatic or Inoperable Locally Recurrent Breast Cancer or Locally Advanced or Metastatic Epidermal Growth Factor Receptor-Mutated Non-small Cell Lung Cancer.","status":"NOT_YET_RECRUITING","sponsor":"AstraZeneca","startDate":"2026-02-27","conditions":"Stomatitis","enrollment":100},{"nctId":"NCT06428409","phase":"PHASE1, PHASE2","title":"A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-06-20","conditions":"Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer","enrollment":220},{"nctId":"NCT06974604","phase":"PHASE2","title":"Preventing Dato-DXd Associated Stomatitis With Dexamethasone Mouthwash, TROPION-DM","status":"RECRUITING","sponsor":"Brown University","startDate":"2025-10-22","conditions":"Breast Neoplasms, Lung Neoplasms","enrollment":60},{"nctId":"NCT06676917","phase":"PHASE2","title":"Datopotamab Deruxtecan (Dato-DXd) for Non-Small Cell Lung Cancer (NSCLC) Patients With Active Brain Metastases","status":"WITHDRAWN","sponsor":"MedSIR","startDate":"2025-06","conditions":"Non-small Cell Lung Cancer","enrollment":""},{"nctId":"NCT06428630","phase":"EARLY_PHASE1","title":"Systemic Absorption of Dexamethasone Oral Rinse in Patients With Oral Lichen Planus","status":"WITHDRAWN","sponsor":"Tufts University","startDate":"2025-05-01","conditions":"Oral Lichen Planus, Oral Lichenoid Reaction","enrollment":""},{"nctId":"NCT03839940","phase":"PHASE3","title":"Dexamethasone in Reducing Everolimus-Induced Oral Stomatitis in Patients With Cancer","status":"TERMINATED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2019-06-03","conditions":"Malignant Neoplasm","enrollment":39},{"nctId":"NCT01698918","phase":"PHASE2","title":"Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast Cancer","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-03-07","conditions":"Hormone Receptor Positive Breast Cancer","enrollment":202},{"nctId":"NCT00391170","phase":"PHASE2","title":"Dexamethasone to Prevent Oral Chronic Graft-versus-Host Disease","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2006-11-24","conditions":"Graft vs Host Disease","enrollment":62},{"nctId":"NCT01983969","phase":"PHASE1, PHASE2","title":"Aza-SAHA-GBM With AutoSCT for Refractory Lymphoma","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2013-11-07","conditions":"Advanced Cancers, Lymphoma","enrollment":61},{"nctId":"NCT04200885","phase":"PHASE4","title":"Is Therapeutic Elastic Bandage As Effective As Corticosteroids Following Third Molar Surgery?","status":"COMPLETED","sponsor":"Tokat Gaziosmanpasa University","startDate":"2019-05-02","conditions":"Third Molar Surgery","enrollment":52},{"nctId":"NCT02589145","phase":"PHASE1, PHASE2","title":"Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC Subtype","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2016-06-22","conditions":"Lymphoma","enrollment":8},{"nctId":"NCT03151876","phase":"PHASE2","title":"Chidamide Combined With Clad/Gem/Bu With AutoSCT in R/R Diffuse Large B Cell Lymphoma","status":"UNKNOWN","sponsor":"Sichuan University","startDate":"2017-06-12","conditions":"Lymphoma","enrollment":93},{"nctId":"NCT02961816","phase":"PHASE2","title":"Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Lymphoma","status":"WITHDRAWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2017-06","conditions":"Lymphoma","enrollment":""},{"nctId":"NCT02069093","phase":"PHASE2","title":"Open-label, Phase II Study of Stomatitis Prevention With a Steroid-based Mouthwash in Post-menopausal Women With Estrogen-receptor-positive (ER+), Human Epidermal Growth Factor Receptor 2 (HER2)- Metastatic or Locally Advanced Breast Cancer","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2014-05","conditions":"Advanced Breast Cancer","enrollment":92},{"nctId":"NCT02735317","phase":"PHASE2","title":"Efficacy and Safety of FORRAD® for the Management of Radiation-induced Mucositis in Patients With Nasopharyngeal Carcinoma Receiving IMRT","status":"UNKNOWN","sponsor":"Yun-fei Xia","startDate":"2016-04","conditions":"Nasopharyngeal Neoplasms, Stomatitis","enrollment":90},{"nctId":"NCT02433899","phase":"PHASE4","title":"Microsurgical Versus Conventional Semilunar Coronally Advanced Flap","status":"COMPLETED","sponsor":"Universidade Federal Fluminense","startDate":"2010-10","conditions":"Gingival Recession","enrollment":14},{"nctId":"NCT02114502","phase":"PHASE2","title":"Carfilzomib/SAHA Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant in Myeloma","status":"WITHDRAWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2014-09","conditions":"Myeloma","enrollment":""},{"nctId":"NCT00686855","phase":"PHASE2","title":"Topical Dexamethasone and Tacrolimus for the Treatment of Oral Chronic Graft-Versus-Host Disease","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2008-08","conditions":"Oral Chronic Graft-versus-host Disease","enrollment":46},{"nctId":"NCT00814359","phase":"PHASE3","title":"Magic Mouthwash Plus Sucralfate Versus Benzydamine Hydrochloride for the Treatment of Radiation-induced Mucositis","status":"COMPLETED","sponsor":"Juravinski Cancer Centre Foundation","startDate":"2009-05","conditions":"Head and Neck Cancer, Mucositis","enrollment":67},{"nctId":"NCT01083420","phase":"PHASE3","title":"The Efficacy of Topical Minocycline in Managing Symptomatic Oral Lichen Planus","status":"UNKNOWN","sponsor":"Sheba Medical Center","startDate":"2010-03","conditions":"Oral Lichen Planus","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":18,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Dexamethasone Mouthwash","genericName":"Dexamethasone Mouthwash","companyName":"Woman's","companyId":"woman-s","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Dexamethasone is a corticosteroid that suppresses local inflammation and immune responses in the oral cavity when applied topically as a mouthwash. Used for Oral inflammation and ulceration, Aphthous ulcers, Oral lichen planus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}